Novo Nordisk’s Pipeline Countdown: MASH Data Due in May, CagriSema Verdict in December

Stock down 13% YTD; CagriSema missed non-inferiority vs Lilly; FDA decision in Dec 2026. MASH data at EASL could boost Wegovy. Key inflection points ahead.

Investors in Novo Nordisk are facing a calendar packed with inflection points. Over the next six months, two distinct sets of clinical data will test whether the Danish drugmaker can broaden its blockbuster GLP-1 platform beyond weight loss and diabetes while simultaneously rehabilitating confidence in its next-generation candidate CagriSema. The stock, down roughly 13 percent year-to-date, has already clawed back some ground from its March low of €30.48, but the recovery remains tentative.

The near-term pressure is real. When one-time accounting effects are stripped out, Novo Nordisk’s first-quarter adjusted revenue fell 4 percent at constant exchange rates, with U.S. sales dropping 11 percent under the same measure. The oral Wegovy pill, launched in the United States on January 5, has generated more than 2 million prescriptions and booked DKK 2.256 billion in Q1 revenue, but that volume growth is being eaten by lower prices. Full-year guidance still calls for adjusted revenue and operating profit to shrink by 4 to 12 percent in constant currency. The stock, now trading near €38.86, is roughly 9 percent below its 200-day moving average — a sign that the medium-term technical picture has not fully healed.

CagriSema, the dual-agonist successor to semaglutide, carries the heaviest burden of proof. The REDEFINE 4 study, published in February, showed the drug achieved a 23.0 percent weight loss over 84 weeks — decent by most measures, but not good enough. Eli Lilly’s tirzepatide delivered 25.5 percent, and CagriSema missed its primary endpoint of non-inferiority. That 809-patient trial, whose participants started at a mean weight of 114.2 kg, left analysts wondering whether Novo Nordisk can still compete in the next obesity race. The company sounds cautiously optimistic that the larger REDEFINE 11 study, due to publish data in the first half of 2027, might produce a better outcome. A higher-dose phase 3 study is also slated to begin in the second half of 2026. Yet the clearest catalyst remains the FDA’s decision on CagriSema for weight management, expected in December 2026 — a verdict that could either salvage the pipeline thesis or deepen the doubts.

Meanwhile, semaglutide’s own expansion story is getting a separate stage. At the EASL congress in Barcelona from May 27 to 30, Novo Nordisk will present fresh analyses from the ESSENCE program, investigating semaglutide 2.4 mg in MASH — a liver condition linked to metabolic dysfunction that affects roughly 250 million people globally. The FDA has already granted accelerated approval for Wegovy in MASH with moderate to advanced fibrosis, and the interim data are striking: 63 percent of patients achieved MASH resolution without worsening fibrosis, versus 34 percent on placebo, while 37 percent saw fibrosis improvement without MASH worsening, against 22 percent in the placebo arm. The upcoming presentations will cover liver safety, subgroup analyses in Japanese and postmenopausal women, and real-world data on disease burden and healthcare costs. If the liver benefits hold up, Novo Nordisk can argue that its platform reaches beyond obesity into adjacent chronic conditions — a narrative that could help offset the CagriSema stumble.

Deutsche Bank, after meeting with research chief Martin Lange, has left its rating unchanged at “Hold” with a target of DKK 290, essentially flat from current levels. Analyst Emmanuel Papadakis sees limited upside and notes that the diabetes study RI4 represents another potential risk. The market seems to be waiting for hard proof: the stock is about 11 percent above its 50-day average, suggesting buyers are not absent, but the year-to-date loss and the cautious analyst view underline that the burden of delivery rests squarely on the company.

Over the next few weeks, the EASL data will offer the first concrete look at how far semaglutide can stretch. Then, on June 7, Novo Nordisk’s R&D investor day at the American Diabetes Association meeting may shed light on the broader clinical direction. By the time the CagriSema FDA decision arrives in December, the pipeline’s credibility — and the stock’s valuation — will have been tested twice.